Chronic Cerebral Ischaemia Stages I-Ii of the Disease: Immune and Metabolic Disorders
Life Sciences-Medicine
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.6.SP23.L57-62Keywords:
Blood Plasma, Chronic Cerebral Ischemia, Hypertension, Immune, Metabolic DisordersAbstract
Due to the increase in average-expectancy life in most developed countries and the environmental deterioration, there has been an increase in cerebrovascular and neurodegenerative diseases. Hence, this study attempts to analyze the chronic Cerebral Ischaemia Stages I-Ii of the disease, immune and metabolic disorders. To fulfil the study’s aim, seventy-five patients of the neurological department of “Kursk Regional Clinical Hospital” suffering from CCI in presence of hypertension, where 32 patients were with the stage I (1st main group) and 43 - with the stage II (2nd main group) at the age of 50 ± 5 years old are examined. In patients with chronic cerebral ischemia (CCI) stages I and II in presence of hypertension, among the 28 studied parameters of the immune and metabolic status of the blood plasma in addition to the content of the C4 component and the complement factor H inhibitor, 92,9% of the indicators were changed from the values of healthy donors at the start of treatment, in the patients with both stages of the disease 73,1% of these parameters turned out to be the same in magnitude and direction of changes, and 26,9% were identical in direction. The data obtained indicate the presence of immune inflammation, oxidative stress, endothelial dysfunction, and activation of lipid peroxidation in patients with CCI. The performed standard pharmacotherapy did not normalize 61,5% of the studied laboratory immune and metabolic indicators changed prior to the treatment in patients with CCI stage I and 76,9% of those with stage II, which, in its turn, makes necessary the correction of immunometabolic disorders at an early stage of the disease, studies of various combinations of preparations with antioxidant, nootropic, metabolic action in complex pharmacotherapy, and the introduction of immunomodulators into the accepted therapeutic regimens are necessary as well.
References
Neurology. National manual/ [E.I. Gusev et al.]. In: Guseva EI, editor Moscow: publishing house of GEOTAR media; 2009. – 637 p. [in Russian].
Damulin IV, Ekushev EV. Dementia due to the lesions of small cerebral vessels: current concepts of pathogenesis and therapy. Neurol Neuropsychiatr Psychosom. 2014;4:94-100. [in Russian].
Gusev EI, Chukanova AS. Modern pathogenetic aspects of chronic cerebral ischemia development. J Neurol Psychiatry. 2015;3:4-8. [in Russian].
Esin RG, Esin OR, Hajrullin IKh. Discirculatory encephalopathy and small vessel ischemic disease. J Neurol Psychiatry. 2016;8:109-13. [in Russian].
Pjehova KA, Mikhin VP, Gavrilyuk EV, Konoplya AI. Immune metabolic disorders in hypertensive disease of varying degree. Bull New Med Technol. 2012;XIX(1):172-3. [in Russian].
Putilina MV. The role the hypertension has in the development of chronic disorders of cerebral circulation. J Neurol Psychiatry. 2014;9:124-8. [in Russian].
Otman IN, Zozulya SA, Sarmanova ZV, Klyushnik TP. Inflammatory and autoimmune reactions in various forms of the nervous system functional impairment. Pathol Physiol Exp Ther. 2015;59(3):81-8. [in Russian].
Tabaeva GR. Clinical phenomenology, mechanisms of formation and pathogenetic therapy for early manifestations of chronic brain ischemia. Clin Pharmacol Ther. 2015;24:81-7. [in Russian].
Gavrilyuk EV, Konoplya AI, Karaulov AV. The role the immune disorders have in the pathogenesis of hypertension. Immunology. 2016;37(1):29-34. [in Russian].
Khaden SA, Gaffen SL. Kolls J.K. Th17 cells at the crossroads of innate and adaptive immunity against infectious deseases at the mucosa // Mucossa Imunol. 2009;2(5):403-11.
Khaitov RM, Ignat’eva GA, Sidorovich IG. Immunology. Norm and pathology. M: OAO ’Publishing house’Medicine; 2010. 752 p. [in Russian].
Yarilin AA. Immunology: textbook. Moscow: GEOTAR media; 2010. 727 p. [in Russian].
Lukens JR, Gross JM, Kanneganti TD. IL-1 family cytokines trigger sterile inflammatory disease. Front Immunol. 2012;3:315. doi: 10.3389/fimmu.2012.00315, PMID 23087690.
Zurochka AV, Davydova EV, Al’tman DSh. Cytokine control of the blood-brain barrier regulation and the levels of non-specific markers of neural tissue damage in patients with early forms of chronic brain ischemia. Russ Immunol Mag. 2013;7(16/4):451-5. [in Russian].
Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G et al. Innate lymphoid cells – aproposal for a uniform nomenclature. Nat Rev Immunol. 2013;13(2):145-9. doi: 10.1038/nri3365, PMID 23348417.
Spencer JD, Schwaderer AL, Becknell B, Watson J, Hains DS. The innate immune response during urinary tract infection and pyelonephritis. Pediatr Nephrol (Berlin, Germany). 2014;l(29 (7)):1139-49.
Gavrilyuk EV, Konoplya AI, Mikhin VP. The immune and oxidant disturbances in patients with acute myocardial infarction and their correction with Mexicor. Kursk scientific-practical [bulletin] “Man and his health”. Vol. 4; 2008. p. 54-60. [in Russian].
Sviridova SP, Sytov AV, Kashiya ShR, Sotnikov AV. The role of nitric oxide in the pathogenesis of sepsis-induced multiple organ failure. Methods of correction. J Intensive Care. 2014;2:8. [in Russian].
Salomatina LV. Clinical diagnostic value of C-reactive protein determination when assessing chronic systemic inflammation. Russ Immunol Mag. 2015;8(17):596-9.
Zotova NV. Features of changes in cytokines levels, soluble intercellular adhesion molecules, and acute phase C-reactive protein in the blood of the patients with varying severity and outcome of sepsis. Russ Immunol Mag. 2015;6(15):266-72. [in Russian].
Gorozhanskaya EG. Free-radical oxidation and the mechanisms of antioxidant defense in a normal cell and in tumor diseases. Clin Lab Serv. 2010;6:28-44. [in Russian].
Kolpakova ME, Vlasov TD, Galagudze MM, Mitrejkin VF. Preconditioning effects of physical factors: the role of reactive oxygen intermediates. Russian physiol. J After I.M. Sechenov. 2014;100(12):1361-73. [in Ruddian].
Markov KhM. Lipoproteins and nitric oxide vascular effects: cellular and molecular mechanisms. Pathol Physiol Exp Ther. 2005;3:2-7. [in Russian].
Gajnullina DK, Kiryuhina OO, Tarasova OS. Nitric oxide in vascular endothelium: the product regulation and mechanisms of its action. Adv Physiol Sci. 2013;44(4):88-102. [in Russian].
Shumilova TE, Nozdrachev AD, Fedorova MA. The role of inorganic nitrite and nitric oxide in the cardiovascular system functioning. Russian physiol. journal after I.M. Sechenov. 2014;100(3):301-15. [in Russian].
Kuznetsova VL, Solov’eva AG. Nitric oxide: properties, biological role, mechanisms of action. Mod Probl Sci Educ. 2015;4:462-72. [in Russian].
Markov KhM. Oxidative stress and endothelial dysfunction. Pathol Physiol Exp Ther. 2005;4:5-9. [in Russian].
Vorob’eva EN, Shumakher GI, Khoreva MA, Osipova IV. Endothelial dysfunction – a key element in the pathogenesis of atherosclerosis. J Cardiol. 2010;2:84-91. [in Russian].
Ivanov AN, Puchin’jan DM, Norkin IA. The barrier function of the endothelium, the mechanisms of its regulation and disorders. Adv Physiol Sci. 2015;46(2):72-96. [in Russian].
Suprun EV, Ischenko AM, Simbirtsev AS, Belenichev IF, Suprun AS. The influence of the receptor antagonist IL-1 on the ratio of thiol-disulfide system, oxidative modification of protein and energy metabolism in the brain cells of rats in presence of experimental hyperglycemia and cerebral ischemia. Cytokines Inflam. 2014;13(2):82-8. [in Russian].
Konoplya AI, Gavrilyuk VP, Loktionov AL, Konoplya AA, Bystrova NA. Clinical experience of immunomodulators, antioxidants and membrane protectors co-use in clinical practice. Kursk: publishing House of the MUP “Kursk city printing house; 2015. 160 p.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Shulginova Anastasiya Aleksandrovna, Litvinova Ekaterina Sergeevna, Bushmina Olga Nikolaevna, Dudka Viktor Tarasovich
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
